Ipsen

Ipsen EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Ipsen (IPN.PA) as of Nov 7, 2026 is 16.15. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 16.29 — a change of -0.84% (lower).

EV/EBITDA

16.15

YoY

-0.84%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Ipsen is 2025 16.15 . EV/EBITDA (Enterprise Value to EBITDA) of Ipsen was 2024 16.29 . It decreases by -0.84% lower compared to the previous year.

The Ipsen EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
23.03 EUR
Jan 1, 2019
19.18 EUR
Jan 1, 2020
17.16 EUR
Jan 1, 2021
14.30 EUR
Jan 1, 2022
13.06 EUR
Jan 1, 2023
15.62 EUR
Jan 1, 2024
16.29 EUR
Jan 1, 2025
16.15 EUR
The Ipsen EV/EBITDA history
YEAREV/EBITDAYoY
16.15-0.84%
16.29+4.30%
15.62+19.60%
13.06-8.70%
14.30-16.65%
17.16-10.50%
19.18-16.73%
23.03-28.70%
32.30-11.28%
36.40-9.30%
40.14-20.65%
50.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

EV/EBITDA (Enterprise Value to EBITDA) of Ipsen is 16.15 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Ipsen changed from 16.29 to 16.15, representing a -0.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Ipsen since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Ipsen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ipsen

All Key Metrics — Ipsen